Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Common Equity (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Common Equity for 11 consecutive years, with $16.8 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 9.49% to $16.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.8 million through Dec 2025, down 9.49% year-over-year, with the annual reading at $16.8 million for FY2025, 9.49% down from the prior year.
  • Common Equity for Q4 2025 was $16.8 million at Marker Therapeutics, down from $18.4 million in the prior quarter.
  • The five-year high for Common Equity was $72.5 million in Q1 2021, with the low at $7.4 million in Q3 2024.
  • Average Common Equity over 5 years is $25.6 million, with a median of $18.5 million recorded in 2024.
  • The sharpest move saw Common Equity tumbled 56.77% in 2022, then skyrocketed 146.84% in 2025.
  • Over 5 years, Common Equity stood at $44.0 million in 2021, then plummeted by 55.44% to $19.6 million in 2022, then decreased by 28.31% to $14.1 million in 2023, then skyrocketed by 32.06% to $18.6 million in 2024, then dropped by 9.49% to $16.8 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $16.8 million, $18.4 million, and $10.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.